Myasthenia Gravis Market Insights, Epidemiology and Market Forecast-2028

DelveInsight Business Research LLP


Albany, NY -- (SBWire) -- 12/23/2019 --Myasthenia Gravis Market Insights, Epidemiology and Market Forecast-2028

(Albany, US) DelveInsight launched a new report on Myasthenia Gravis Market Insights, Epidemiology and Market Forecast-2028

Some of the key facts of the report
1. There were approximately 129,267 prevalent cases of Myasthenia Gravis in 2016 in 7MM.
2. The United States accounts for the highest Myasthenia Gravis prevalence, followed by EU5 and Japan.
3. Among the European countries, Spain had the highest Myasthenia Gravis prevalence with around 15,275 cases, followed by Germany with about 12,400 cases in 2016.
4. Japan had the lowest prevalent population of Myasthenia Gravis in 2016, with 14,985 cases.

Key benefits of the report

1. Myasthenia Gravis market report covers a descriptive overview and comprehensive insight of the Myasthenia Gravis epidemiology and Myasthenia Gravis market in the 7 MM (the United States, EU5 (Germany, Spain, France, Italy, UK) & Japan.)
2. Myasthenia Gravis market report provides insights on the current and emerging therapies.
3. Myasthenia Gravis market report provides a global historical and forecasted market covering drug outreach in 7 MM.
4. Myasthenia Gravis market report offers an edge that will help in developing business strategies by understanding trends shaping and driving the Myasthenia Gravis market.

Request for sample pages

"Myasthenia Gravis is more prevalent in females as compared to males, with around 38,775 female and 25,850 male cases in 2016 in the United States."

The Market analysis carried out from 2016 to 2027 demonstrates that Myasthenia Gravis Market size was found out to be USD 2998.1million in 2016 in 7MM. At present, the therapeutic Myasthenia Gravis market size is mainly accounted by symptomatic treatment including acetylcholinesterase Inhibitors (Mestinon), corticosteroids, immunosuppressants (azathioprine, cyclosporine, cyclophosphamide, methotrexate, mycophenolate mofetil, rituximab, tacrolimus), rapid-acting short-term immunomodulation (Intravenous Immunoglobulin, Plasma Exchange), and long-term immunomodulation (Thymectomy). Recently, Soliris (Eculizumab) (Alexion Pharmaceuticals) got approval for Myasthenia Gravis treatment in the year 2017. The monoclonal antibody (MAB) inhibits acetylcholine receptor antibodies from affecting muscle cells and is helpful for patients resistant to the other available therapies. About this, many companies are investing in the Myasthenia Gravis monoclonal antibody market. They are looking for the treatment of patients other than AchR antibodies, such as MUSK antibodies since there is no treatment for MUSK antibody-positive patients in the Myasthenia Gravis market till now.

The launch of the emerging therapies is expected to significantly impact Myasthenia Gravis treatment scenario in the upcoming years:-
Drugs covered
1. Rozanolixizumab
2. CFZ533
3. Efgartigimod
4. RA101495
6. Firdapse
7. Hizentra
And many others

The key players in Myasthenia Gravis market are:
1. UCB Pharma
2. Novartis
3. Argenx
4. Ra Pharmaceuticals
5. Grifols Therapeutics
6. Catalyst Pharmaceuticals
7. CSL Behring
8. And many others

Table of contents
1. Key Insights
2. Myasthenia Gravis Market Overview at a Glance
3. Myasthenia Gravis Disease Overview
4. Myasthenia Gravis Epidemiology and Patient Population
5. Country Wise Myasthenia Gravis Epidemiology
5.1. United States
5.2. Germany
5.3. France
5.4. Italy
5.5. Spain
5.6. United Kingdom
5.7. Japan
6. Myasthenia Gravis Current Treatment Practices
7. Unmet Needs
8. Myasthenia Gravis Marketed drugs
8.1. Key cross competition- Marketed drugs
8.2. Mestinon: Valeant Pharmaceuticals
8.3. Soliris: Alexion Pharmaceuticals
8.4. Prograf: Astellas Pharma
8.5. Venoglobulin IH: Mitsubishi Tanabe Pharma
9. Myasthenia Gravis Emerging Therapies
9.1. Key cross competition- Emerging Therapies
9.2. Rozanolixizumab: UCB Pharma
9.3. CFZ533: Novartis
9.4. Efgartigimod : Argenx
9.5. RA101495: Ra Pharmaceuticals
9.6. Firdapse: Catalyst Pharmaceuticals
9.7. Hizentra: CSL Behring
9.8. IGIV-C: Grifols Therapeutics
10. Myasthenia Gravis 7 Major Market Analysis
11. Market Outlook by Country
11.1. The United States: Market Outlook
11.2. United States Market Size
11.3. EU-5 Countries: Market Outlook
11.4. Germany
11.5. France
11.6. Italy
11.7. Spain
11.8. United Kingdom
11.9. Japan: Market Outlook
12. Market Drivers
13. Market Barriers
14. Appendix
15. DelveInsight Capabilities
16. Disclaimer
17. About DelveInsight

About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Contact us:
Shruti Thakur
SOURCE DelveInsight

Media Relations Contact

Priya Maurya

View this press release online at: